German Version French Version


Duloxetine, (+)-(S)-N-Methyl-3-(naphyloxy)-3-(2-thienyl)propylamine, C18H19NOS, M 297,42

Serotonine and norepinephrine reuptake inhibitor (SNRI)

Brand name: Cymbalta, Yentreve



Yentreve: women stress urinary incontinence (SUI)
Cymbalta: Treatment of moderate to severe major depressive disorders and diabetic peripheral neuropathy


Duloxetine should not be used in patients with: liver or kidney diseases, epileptic diseases, patients under 18 years.


After treatment with MAO-inhibitors, Duloxetine should be taken only after expiration of a 14 days period, in order to avoid an occurrence of the serotonine syndrome.

Adverse Effects

In particular at the beginning nausea, tiredness or sleep disturbances arises. Further on sexual problems are reported. When the setting off from Duloxetin is too fast, fear conditions could arise with a potential higher suicide risk.

Custom Search




Last modification (M-D-Y): 02/08/2019 - IMPRINT - FAQ